Literature DB >> 32405694

Daratumumab for refractory warm autoimmune hemolytic anemia.

Ankur Jain1, D K Gupta2.   

Abstract

Entities:  

Year:  2020        PMID： 32405694     DOI： 10.1007/s00277-020-04063-w

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  1 in total

1.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Authors:  T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701
  1 in total
  5 in total

Review 1.  Development of New Drugs for Autoimmune Hemolytic Anemia.

Authors:  Zhengrui Xiao; Irina Murakhovskaya
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

2.  Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome.

Authors:  Daniel E Pleguezuelo; Raquel Díaz-Simón; Oscar Cabrera-Marante; Antonio Lalueza; Estela Paz-Artal; Carlos Lumbreras; Antonio Serrano Hernández
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

3.  The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease.

Authors:  Anna Zaninoni; Juri A Giannotta; Anna Gallì; Rosangela Artuso; Paola Bianchi; Luca Malcovati; Wilma Barcellini; Bruno Fattizzo
Journal:  Front Immunol       Date:  2021-03-01       Impact factor: 7.561

4.  Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report.

Authors:  Lake R Crawford; Natalia Neparidze
Journal:  Clin Case Rep       Date:  2022-03-18

5.  Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia.

Authors:  Etienne Crickx; Sylvain Audia; Ailsa Robbins; David Boutboul; Thibault Comont; Morgane Cheminant; Eric Oksenhendler; Bertrand Godeau; Marc Michel; Matthieu Mahevas
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.